It was subsequently observed that antagonists of the σ2R were able to block the neuronal uptake of Aβ oligomers in cultured neurons, which led to the exploration of σ2R ligands as potential drugs for delaying the clinical progression of Alzheimer’s disease (AD) [8]. Here, TMEM97 is linked to early-onset autosomal dominant Alzheimer disease.